Melanoma
Conditions
Brief summary
Currently, the first line treatment options for surgically unresectable metastatic melanoma includes anti-PD1 agents such as nivolumab and pembrolizumab. In western countries, UV associated cutaneous melanoma has 30-40% response rates to immune checkpoint inhibitors (ICIs). However, response rates are lower in Asians. The reason for this discrepancy is attributed to the difference in subtypes since most of the Asian patients are mostly subgrouped as acral lentiginous or mucosal types that are unrelated to UV exposures. Thus, there is an unmet need to bolster the effect of ICIs in these patients. The combination of radiotherapy with ICIs have been demonstrated by several pre-clinical studies. High dose radiation has shown to promote STING pathway which activates dendritic cells needed in priming phase. In addition, low dose radiation may activate macrophage differentiation. These mechanisms in turn may enhance responses to immunotherapy. In this study, the investigators aim to evaluate the efficacy and tolerability of anti-PD-1 blockade in combination with radiotherapy in surgically unresectable, treatment naive metastatic melanoma.
Interventions
DRUGThe combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab)
Subjects with treatment naïve, surgically unresectable metastatic melanoma stages IIIB to IVM1c will be treated with combination of anti-PD1 (pembrolizumab or nivolumab) and radiotherapy.
Sponsors
Yonsei University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* 1\. Subject has provided informed consent prior to initiation of any study-specific activities/procedures * 2\. Male or female age \> 20 years at the time of informed consent * 3\. Histologically confirmed diagnosis of unresectable stage III or IV melanoma as per AJCC staging system 8th edition * 4\. Subject with no prior systemic treatment * 5\. Eastern Cooperative Oncology Group (ECOG) Performance Status \< 1 * 6\. Screening labs performed within 7 days of randomization demonstrating adequate hematologic, coagulation, liver, and kidney functions * 7\. Indications for radiotherapy * 8\. BRAF status must be checked, but patient is eligible regardless of BRAF mutations (BRAF V600 wild type or BRAF V600 mutation positive are both eligible)
Exclusion criteria
* 1\. Ocular melanoma * 2\. Active brain metastasis (stable after 1 month of radiotherapy, gamma knife surgery or surgery) * 3\. Requires palliative radiotherapy * 4\. Previous treatment with chemotherapy, a CTLA-4 or PD-1/PD-L1 antagonist agent, including treatment in adjuvant setting * 5\. Autoimmune disease requiring chronic treatment with systemic corticosteroids or any other immunosuppressive agents 7 days prior to inclusion. (physiologic dose of prednisolone 10mg or equivalent are accepted) * 6\. Concurrent medical disease which would significantly limit full compliance with the study such as, but not limited to the following: heart failure (III, IV as per NYHA classification), renal insufficiency, active infection (requires negative gest for clinically suspected HIV, hepatitis B virus, hepatitis C virus). If positive results are not indicative of true active or chronic infection, the subject may enter the study after discussion and agreement between the investigator and medical director. * 7\. Has known malignancy that is progressing and requires active treatment * 8\. Has known psychiatric or substance abuse disorders that would interfere with cooperation requirements of the trial * 9\. Lack of availability for clinical follow-up assessments
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate (ORR) | 1 year | assessment of efficacy of anti-PD1 with radiotherapy in terms of overall response rate (ORR) |
Secondary
| Measure | Time frame |
|---|---|
| treatment-related adverse events (TRAE) | 3 years |
| rate of progression-free survival (PFS) | 1 year |
| overall survival (OS) | 1 year |
| disease control rate (DCR) | 1 year |
Countries
South Korea
Contacts
Primary ContactSang Joon Shin, MD, Ph.D
Outcome results
None listed